NCT02950441

Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype

Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: University of Birmingham · Academic / Other
• Sex: Male
• Age: 70 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study is designed to assess the physiological consequences of elevating Nicotinamide Adenine Dinucleotide (NAD+) availability using Nicotinamide Riboside (NR) supplementation in skeletal muscle tissue, and examine its effect upon muscle metabolic phenotype.

Detailed description

-NAD+ sensitive metabolic decline in ageing, including sarcopenia, leads to a reduction in energy metabolism, contribute to chronic inflammation, disposing individuals to metabolic disease and overall decreased later-life health. Prominent metabolic changes include a decline in NAD+ content and deterioration in muscle NAD+ mediated signalling and mitochondrial function, ultimately compromising skeletal muscle and whole body energy homeostasis. The most efficient means to boost NAD+ in muscle appears to be oral delivery of NR, and participants will be supplemented with 1000mg NR (2x x250mg tablets twice daily) for 3 weeks. * Hypothesis: elevating skeletal muscle NAD+ bioavailability using NR supplementation will increase markers of mitochondrial function and that will manifest as a more favourable metabolic profile. * Study Setting: the study will be carried out at the NIHR/Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham.

Conditions

• Aging

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nicotinamide Riboside
OTHER	Placebo

Timeline

• Start date: 2016-06-01
• Primary completion: 2018-09-01
• Completion: 2019-09-01
• First posted: 2016-11-01
• Last updated: 2017-06-07

Locations

1 site across 1 country: United Kingdom